



AN ANNUAL
BREAST CANCER
SCREENING TEST

Rx Only

Trucheck[™]
Breast Cancer



DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA

Why should I consider Cancer Screening?

Cancer is a ticking time bomb globally. Every year about 18 million women and men are diagnosed with various cancers including carcinomas, sarcomas, neuroendocrine tumors and melanomas. These cancers are also associated with about 9 million deaths. This translates into roughly 34 cancer cases being detected and 18 cancer related deaths every minute. Annually, these cancers contribute to:

- ~4.1 million newly diagnosed cases and 1.8 million deaths in Europe (including the UK).
- ~2.1 million newly diagnosed cases and 550,000 deaths in the US.
- ~1.2 million newly diagnosed cases and 760,000 deaths in India.

Due to changes in lifestyle as well as other risk factors, these numbers are slated to increase in the future. Detecting cancer early is vital to saving lives. Studies have shown that early detection of cancer improves survival rates.

Trucheck™ is a blood test that can enable early detection of multiple cancers in asymptomatic individuals.




Breast Cancer

Several healthcare organizations globally support breast cancer screening for early detection. While mammography has some inherent challenges associated with age and breast density, Trucheck™-Breast non-invasive blood test can detect early stages with high sensitivity.




Why should I consider Trucheck™?

- Circulating Tumor Cells (CTCs) and their clusters are present in the blood of almost all cancer patients and are undetectable even in seemingly healthy individuals.
- Trucheck™ technology to detect and characterise CTCs has been proven through extensive clinical validations involving more than 40,000 participants.
- The test is a paradigm shift in cancer screening, as it does not involve radiation or invasive procedures. The test is performed at our world-class laboratory, which meets and exceeds all national and international standards.



Illustrative images of breast cancer circulating tumor cells



Advantages of Trucheck™?

Being a non-invasive blood-based test, Trucheck™ can minimize the need to visit a healthcare centre – since the blood sample can also be collected from the privacy and comfort of your home.

Advantages to the individuals:

1. Wait times for appointments are reduced
2. Minimized risk of COVID exposure
3. May be assimilated into annual health check-up
4. No risk of radiation or those associated with invasive procedures

Advantages to the system:

1. Reduces risk of COVID transmission and exposure of staff
2. Reductions in avoidable / non-critical appointments
3. Minimizes procedures that may be retrospectively deemed unnecessary
4. Supports decision making in conjunction with existing tests / methods



1. Does Trucheck™ detect ‘existence of cancer’ or ‘possibility of cancer’?

Trucheck™ detects ‘existence of cancer’.

2. Does Trucheck™ replace conventional cancer screening like mammography?

Trucheck™ is not intended to be and should not be considered as a replacement for any Standard of Care screening tests.

3. Does a ‘negative’ Trucheck™ result mean that I am ‘totally’ cancer free?

Within the limits of error, a ‘negative’ result is a reasonable indication of undetectable cancer of the type covered by the test. For other cancers not covered by the test, no inference should be drawn from a ‘negative’ result.

4. Does a ‘negative’ Trucheck™ result mean that I am free from cancer forever?

A ‘negative’ result means that at the time of the test there were no detectable cancer cells circulating in the blood.

5. How frequently should Trucheck™ be repeated?

As Trucheck™ is a non-invasive blood test, there is no disadvantage in frequent testing. However, we advise that Trucheck™ should be performed every 12 months in case of negative result.

7. Is Trucheck™ recommended for a person suspected to have / has symptoms of cancer?

No, such individuals should seek expert medical advice without delay.

8. Can Trucheck™ be used to monitor recurrence after cancer treatment?

No.

Trucheck™ – Research

Cancer
Prevention
Research

AACR
American Association
for Cancer Research

CANCER PREVENTION RESEARCH | RESEARCH BRIEF

Hallmark Circulating Tumor – Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk

Cancer Cytopathology



ACS JOURNALS

Evaluation of Circulating Tumor Cell Clusters for Pan-Cancer Noninvasive Diagnostic Triaging



IJC

International Journal of Cancer

Circulating Ensembles of Tumor – Associated Cells: A Redoubtable New Systemic Hallmark of Cancer



DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA

Accreditations for Our Lab in India



CLIA
Accredited Laboratory
No.: 99D2171983



Advena Ltd. Tower Business Centre, 2nd Flr.,
Tower Street, Swatar, BKR 4013, Malta

Contact us:

✉ enquiry@lifeomicsdx.com 🌐 datarpgx.com

Proprietary Technology, All Intellectual Property Rights Protected under relevant laws.